NCT03537586Active, not recruiting
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
Among patients with stable ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (CAD). Ischemia based on symptoms or stress testing may be due to coronary microvascular dysfunction in up to 40% of these patients. However, the mechanisms and optimal treatment of coronary microvascular dysfunction are unknown. Aberrant platelet activity and inflammation have been hypothesized as mechanisms of microvascular dysfunction. Investigators plan to evaluate association between platelet activity, inflammation, and coronary microvascular dysfunction in stable women referred for coronary angiography, and to identify non-invasive correlates of coronary microvascular dysfunction in these patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 206 (actual)
- First submitted
- 15 May 2018
- Start date
- 29 Jun 2018
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- NYU Langone Health
- Diseases
- Coronary artery disease
- NCT number
- NCT03537586
What you commit to
- Study type: Interventional
- Participants enrolled: 206
- From 29 Jun 2018 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior percutaneous coronary intervention or coronary artery bypass grafting
Other illness
- Active bleeding and/or bleeding diathesis
- Acute myocardial infarction within 3 months
- Severe valvular heart disease
- New York Heart Association (NYHA) Functional Class III or IV heart failure
- Contraindication to intravenous infusion of adenosine during coronary angiography, due to known hypersensitivity to adenosine, known or suspected bronchoconstrictive or bronchospastic lung disease (severe asthma), second- or third-degree AV block (except in patients with a functioning artificial pacemaker), or sinus node disease, such as sick sinus syndrome or symptomatic bradycardia,
- Angiographic Exclusion criteria:
Lab values
- Anemia (hemoglobin \<9 mg/dl)
- Known thrombocytosis (platelet count \>500,000)
- Know thrombocytopenia (platelet count \<100,000)
- Platelet antagonists other than aspirin and thienopyridines, within 7 days
- Ejection Fraction \<40%
Other
- Pre-Cath Exclusion criteria:
- NSAIDs (e.g., ibuprofen, naproxen) within 3 days
- Cardiogenic shock or mechanical circulatory support
- Hypertrophic obstructive cardiomyopathy or severe left ventricular hypertrophy
- Pregnancy
- Obstructive CAD (≥50% luminal obstruction in ≥1 major epicardial coronary arteries by invasive coronary angiography)
- Unfavorable coronary artery anatomy for guidewire positioning (as determined by the angiographer or PI)
Who the study is looking for
- Adult women age ≥18 years referred for coronary angiography
- Stable ischemic heart disease, defined by ischemic symptoms and/or myocardial ischemia by stress testing
- Administration of aspirin therapy prior to cardiac catheterization
Age in the registry: 18 years to 125 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| New York University School of Medicine Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.